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WaldenströmMacroglobulinemia (WM) is definedby the presence of an indolent lymphoplasma-cytic lymphoma (LPL) (monoclonal lympho-cytes, lymphoplasmacytes and plasma cells (PC)
in the bone marrow (BM)) and monoclonal IgM protein
secretion.1,2 Therefore, a BM biopsy showing LPL infiltration
is currently essential to define WM; nevertheless, sometimes the
pathological diagnosis can be troublesome: actually, the preva-
lence of monoclonal PC might suggest a diagnosis of multiple
myeloma (MM), while in other cases, when small lymphocyte
infiltration is predominant, the differentiation with other
lymphomas can represent a challenge, both at morphologic
and at immunophenotypic exam. In addition, the BM biopsy is a
rather invasive surgical procedure and might represent a
diagnostic limitation, in particular when dealing with elderly
or unfit patients. Moreover, both the risk of relapse and the
sensitivity to novel drugs are still difficult to predict in WM.
Finally, some particular IgM-associated conditions (eg, demye-
linating polyneuropathy) are still not well characterized.
Recently, a novel method to detect in different tissues the
MYD88L265P mutation,3,4 a hallmark of WM, has been
described: the droplet digital PCR (ddPCR) assay.5 In this paper
clinical reports of useful applications of this sensitive and reliable
tool in daily practice are described, in a question & answer form.
Might MYD88 be useful for non-invasive
differential diagnosis of WM vs IgM-MM?
MB, a 62 years-old male, presented with fatigue, dyspnea,
headache and tinnitus. Blood exams revealed mild anemia (Hb
11.5g/dl), an IgMvalue of 6334mg/dl and an IgMkM-component
(MC) of 3410mg/dl, so a BM biopsy was performed (Fig. 1A–C).
An excess of clonal PCs (nearly 60%)was found, at first suggesting
the diagnosis of IgM-MM, while immunophenotype reported
indolent B lymphoma infiltration. Interestingly, the clonal PCs did
not present the chromosomal translocations typical of MM by
fluorescent in situ hybridization (FISH); finally, ddPCRon BM, PB
and plasma were positive for the MYD88L265P mutation and a
diagnosis of WM was established. The patient then started
dexamethasone-rituximab-cyclophosphamide (DRC) treatment
preceded by plasmapheresis, achieving partial remission (PR).
Comment
Most of PC dyscrasias are attributable to MM, however, there
are some exceptions: an IgG MC can be also attributable to rare
cases of IgG-LPL or other indolent lymphomas, and similarly,
some cases of IgMMC are due to aggressive IgM-MM and not to
WM. In particular, because of its LPL-like pathological and
phenotypical features, IgM-MM can be often mistaken for WM;
however, as reported also by Treon et al,6 these cases areMYD88
wild-type. So, in this setting, when laboratory findings seem
discordant, or the BMbiopsy is uncertain or not available, the non-
invasiveMYD88 evaluation can support the differential diagnosis.
Might MYD88 be useful to refine the diagnosis
of B-cell lymphoma?
AL, a 68-years-old male, presented with multiple lymphade-
nopathies and an IgMk MC at 680mg/dl. The cervical lymph
node biopsy was inconclusive, showing diffused small B-cell
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lymphoma CD20+, CD10+, BCL2+, IgD+, CD23+/, with
uncertain differential diagnosis between diffuse follicle center and
marginal zone lymphoma, MZL. The BM biopsy revealed a
small B-cell population with secretory differentiation and clonal
IgMk lymphoplasmacytic population (20%) (Fig. 1D–G). The
MYD88L265P detection by ddPCR in BM and plasma finally
supported the diagnosis of WM, so the patient underwent a DRC
therapy, achieving complete remission.
Comment
The differential diagnosis of small cell lymphomas with a
diffuse pattern can be troublesome. Both the lymph node and the
BM biopsy can be inconclusive, even after extensive flow
cytometric and immunohistochemical characterization. There-
fore, the availability of a sensitive and non-invasive tool, as the
ddPCR MYD88L265P assay, might help in choosing the most
appropriate therapy.
Might MYD88 be used as a non-invasive
marker to early identify WM relapse?
GT, a 76-years-old female patient, was diagnosed with
symptomatic WM and underwent a cyclophosphamide-
vincristine-prednisone (CVP) therapy, obtaining PR. Four years
later, a mild but progressive increase of IgM value was observed
(2489mg/dl), concurrently with anemia andworsening of general
conditions. The patient received R-Bendamustine therapy, again
achieving PR. Two years later, the patient presented with fatigue
and weight loss, without worsening of blood exams (Hb 12.6g/
dl, IgM 1069mg/dl); nevertheless, after 6 months, the appearance
of pancytopenia and splenomegaly (in absence of IgM increase)
suggested to repeat the BM biopsy, with a final diagnosis of
progressive WM. A retrospective study of the MYD88L265P
mutation on PB by ddPCR showed rising values several months
before the insurgence of symptoms (Fig. 2A).
Comment
In pre-treated WM patients, the appearance of cytopenia may
be due to different causes (eg, chronic blood loss anemia,
myelodisplastic syndrome, acute leukemia), rather than directly
related to relapsing disease.7 Moreover, a depletion of the
secretory fraction often occurs in heavily treated patients, as well
as an isolated IgM suppression may occur independently of
cytotoreduction when using mTOR and BTK inhibitors,8 leading
to discordant serological/histological results. Therefore, the mere
Figure 2. Comparison between MYD88L265P, hemoglobin, and IgM values during the follow-up (A). MYD88L265P levels in BM, PB and cell-free DNA
(cfDNA) from diagnosis to the present (B).
Figure 1. BM biopsy showing nuomerous lymphoplasmacytic cells (A) that are CD20+ (B) and CD138- (C). BM biopsy showing a diffuse small cell
population (D) positive for CD20 (E) and k light chain (F), negative for l light chain (G).
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IgM levels are not sufficiently reliable for relapse prediction.
Actually, BM biopsy is essential to differentiate among these
conditions, but non-invasive evaluation of theMYD88 mutation
might act as a diagnostic support.
Might MYD88 monitoring be used as an early
response predictor to describe the activity of
new treatments?
DM, a 43-years-old male, in 1997 was diagnosed with
symptomatic WM and underwent high dose sequential (HDS)
therapy followed by autologous stem cell transplantation. After
5 years, a slow but progressive increase of the MC was observed,
leading to large lymphadenopathies and massive BM infiltration
9 years later. Therefore, a rituximab-citarabine-bortezomib
therapy was started, resulting in PR. Again, after 3 years, an
increase of the abdominal lymphadenopathies was observed,
with anemia and risingMC: the patient started ibrutinib therapy,
with complete resolution of anemia, MC reduction >50%,
lymphadenopathies stability. The patient is now in good health
and has been on ibrutinib treatment for 30 months.
A retrospective analysis of the MYD88L265P levels in BM by
ddPCR showed persistent positivity during the follow-up, with
a transient, deep reduction after the bortezomib-containing
therapy and a slighter but constant decrease during ibrutinib
(detectable in PB and plasma, too) (Fig. 2B).
Comment
Although WM is traditionally managed as an indolent and
constantly relapsing disease, modern chemo-immunotherapies
containing rituximab, bendamustine, bortezomib, as well as the
new drugs carfilzomib and venetoclax9,10,11 resulted in major
cytoreduction. Therefore, MRD analysis might provide a more
accurate evaluation of the efficacy of novel treatments, rather than
the simple clinical response. Actually, MYD88L265P ddPCR assay
can overcome the limited feasibility of the IGH-based approach,5,12
providing a stable molecular marker virtually to all WM patients.
Moreover, the data on cell-free DNA (cfDNA) seem to nicely reflect
theBMstatus, thus representing anon-invasive alternative forMRD
detection. Nevertheless, the role of MRD in WM is not as well
characterized as it is in other indolent lymphomas, so far, and its
clinical impact is still under evaluation.13
Might ddPCR be useful to identify MYD88
mutation in pre-treated patients?
LF, a 62-years-old male, presented with diffused lymphade-
nopathy and anemia (Hb 10.9g/dl). The serum protein
electrophoresis showed a MC of 1585mg/dl (IgM value 2730
mg/dl), so lymph node and BM biopsy were performed and a
diagnosis of WM was made. The MYD88L265P screening by
ddPCR was positive on BM. The patient underwent a DRC
therapy, but at the end of treatment the CT scan revealed a SD,
along with no serological response (IgM 2438mg/dl); actually,
MYD88L265P resulted negative on PB, but still positive on
plasma. Finally, the patient was referred to bendamustine-
rituximab-bortezomib (BRB)12 experimental therapy.
Comment
In patients pre-treated with rituximab, non-invasive
MYD88L265P evaluation in PB is not reliable because of the
high rate of false negative results,5 likely due to the high clearance
of circulating lymphoma cells. Therefore, BM or plasma analysis
is advisable in pre-treated cases to identify themutation. Actually,
in paired analysis the median mutational load in PB samples is
1 log lower, compared to BM; conversely, between BM and
plasma-cfDNA no statistically significant differences were
reported.5 Moreover, a similar underestimation ofMYD88L265P
was described in PB samples of pre-treated vs rituximab-naïve
patients, both in terms of mutational detection rates (about 40%
of false negatives) and of median quantitative burden (about 1 log
lower).5
This clue is particularly relevant when MYD88 mutational
status is investigated as response predictor to targeted therapies,
such as to prescribe BTK-inhibitors vs a different relapse
treatment.14
Might MYD88 be useful to supplement the
diagnosis of anti-mag polyneuropathy?
DF, a 54-years-old male, presented with lower limbs
paresthesia. An electroneurography (ENG) showed the presence
of a demyelinating polyneuropathy. The evaluation for anti-
myelin-associated glycoprotein antibodies (MAG) resulted posi-
tive and the IgM value was 307mg/dl (no MC at protein
electrophoresis nor at immunofixation). A BM biopsy revealed
the presence of a LPL, and theMYD88L265P screening by ddPCR
was positive on BM, PB and plasma. Based on the presence of LPL
and a progressive anti-MAG polyneuropathy, the patient
underwent 4 rituximab infusions. At the end of therapy, the
IgM value was 175mg/dl, theMYD88 screening was negative on
PB and plasma (BM biopsy was not repeated) and the ENG
revealed a clear reduction of the demyelinization signs.
Comment
Anti-MAG demyelinating polyneuropathy is a rare, disabling
and still under-characterized disease that can be associated either
to WM/LPL or to IgM-MGUS. The prevalence of MYD88L265P
mutations in anti-MAG neuropathy patients has been recently
shown to be comparable to those observed in WM and MGUS
control groups. Since there is actually no consensus on the
optimal treatment strategy for anti-MAG neuropathies, detecting
MYD88L265P mutation even in non-invasive tissues might help
to reveal a smoldering WM, identifying patients for which
rituximab treatment may be of benefit.15,16,17
In conclusion, the ddPCR MYD88L265P assay might have
several clinical applications (Fig. 3):
1) driving the differential diagnosis with IgM-MM and small
lymphocytes, Ig-secreting disorders;
2) easy-to use molecular marker for MRD, particularly to
measure the efficacy of new drugs;
3) predictive biomarker of response to ibrutinib treatment;
4) supporting the diagnosis of WM as underlying disease for rare
IgM-related disorders (eg, anti-MAG polyneuropathy).
The ddPCR MYD88L265P assay also presents important
advantages compared to other available techniques (as qPCR
or NGS): actually, it is non-invasive, cheap, fast, easily applicable
to clinical routine and clinical trials, standardizable and promptly
scalable to other mutations of interest (eg, CXCR4).
Therefore, this assay is rapidly finding its role both
for mutational screening and for MRD monitoring in ongoing
(BRB, EudraCT Number: 2013-005129-22 and BIO_WM, ID:
(2020) Vol:No www.hemaspherejournal.com
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NCT03521516) and future (ECWM-2, EudraCT Number:
2017-004362-95) clinical trials.
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Figure 3. Clinical applications of the ddPCR MYD88L265P assay in WM.
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